Legal & General Group Portfolio holdings
Legal & General Group Plc, founded in 1836 by six lawyers in London, is a British multinational financial services company headquartered in London, renowned for its leadership in insurance, pensions, and investment management. Managing trillions in assets, the firm operates through key divisions like Legal & General Investment Management (LGIM), one of the UK’s largest asset managers, focusing on index funds, active strategies, and sustainable investing for institutional clients like pension funds. It also provides life insurance, retirement products, and general insurance, serving millions of customers with a strong emphasis on long-term financial security and infrastructure investment, such as affordable housing. With a heritage of stability and a modern push toward ESG (environmental, social, governance) principles, Legal & General remains a cornerstone of the UK financial landscape with a growing global presence.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$261M |
| 2 |
Alibaba
BABA
|
+$233M |
| 3 |
Truist Financial
TFC
|
+$191M |
| 4 |
Microsoft
MSFT
|
+$160M |
| 5 |
Amazon
AMZN
|
+$133M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$415M |
| 2 |
STI
SunTrust Banks, Inc.
STI
|
+$186M |
| 3 |
VIAB
Viacom Inc. Class B
VIAB
|
+$73.8M |
| 4 |
Oracle
ORCL
|
+$25.8M |
| 5 |
CBLK
Carbon Black, Inc. Common Stock
CBLK
|
+$23.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.21% |
| 2 | Financials | 15.12% |
| 3 | Healthcare | 12.68% |
| 4 | Consumer Discretionary | 10.28% |
| 5 | Communication Services | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FLIC
2426
DELISTED
First of Long Island Corp
FLIC
| $176K | ﹤0.01% |
7,017
| – | – |
|
|
YMAB
2427
DELISTED
Y-mAbs Therapeutics
YMAB
| $175K | ﹤0.01% |
5,599
+2,207
| +65% | +$65.3K |
|
2428
Vericel Corp
VCEL
$2.32B
| $174K | ﹤0.01% |
10,004
+1,735
| +21% | +$29.5K |
|
2429
Waterstone Financial
WSBF
$377M
| $174K | ﹤0.01% |
9,161
+71
| +0.8% | +$1.31K |
|
2430
Texas Pacific Land
TPL
$26.3B
| $173K | ﹤0.01% |
1,989
| – | – |
|
|
ATRS
2431
DELISTED
Antares Pharma, Inc.
ATRS
| $173K | ﹤0.01% |
36,870
+6,316
| +21% | +$25.8K |
|
|
DERM
2432
DELISTED
Dermira, Inc.
DERM
| $173K | ﹤0.01% |
11,440
+1,920
| +20% | +$16.6K |
|
2433
Bally's
BALY
$686M
| $170K | ﹤0.01% |
6,642
+3,259
| +96% | +$78.5K |
|
|
TVRD
2434
Tvardi Therapeutics
TVRD
$25M
| $170K | ﹤0.01% |
292
+36
| +14% | +$25.3K |
|
|
GOOD
2435
Gladstone Commercial Corp
GOOD
$593M
| $169K | ﹤0.01% |
7,758
+357
| +5% | +$8.1K |
|
|
EIGI
2436
DELISTED
Endurance International Group Holdings, Inc.
EIGI
| $169K | ﹤0.01% |
35,913
+2,834
| +9% | +$11.6K |
|
2437
Gran Tierra Energy
GTE
$334M
| $168K | ﹤0.01% |
12,941
| – | – |
|
2438
Intellia Therapeutics
NTLA
$1.53B
| $168K | ﹤0.01% |
11,476
+1,326
| +13% | +$18.4K |
|
2439
Prothena Corp
PRTA
$444M
| $167K | ﹤0.01% |
10,560
| – | – |
|
|
SILK
2440
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $167K | ﹤0.01% |
4,140
+2,194
| +113% | +$76.8K |
|
2441
UroGen Pharma
URGN
$2.26B
| $166K | ﹤0.01% |
4,973
+746
| +18% | +$20.4K |
|
2442
Akebia Therapeutics
AKBA
$346M
| $165K | ﹤0.01% |
26,051
| – | – |
|
|
AXDX
2443
DELISTED
Accelerate Diagnostics
AXDX
| $165K | ﹤0.01% |
977
+149
| +18% | +$24.6K |
|
2444
Ennis
EBF
$562M
| $165K | ﹤0.01% |
7,626
| – | – |
|
2445
Rhythm Pharmaceuticals
RYTM
$7.62B
| $164K | ﹤0.01% |
7,144
+2,927
| +69% | +$65K |
|
|
TBIO
2446
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $164K | ﹤0.01% |
20,146
+15,193
| +307% | +$140K |
|
2447
Independent Bank Corp
IBCP
$791M
| $163K | ﹤0.01% |
7,202
+223
| +3% | +$4.93K |
|
2448
Krystal Biotech
KRYS
$9.64B
| $163K | ﹤0.01% |
2,940
+414
| +16% | +$20.3K |
|
2449
OneSpaWorld
OSW
$2.7B
| $161K | ﹤0.01% |
9,590
+2,039
| +27% | +$32.1K |
|
2450
Tidewater
TDW
$3.85B
| $161K | ﹤0.01% |
8,328
+346
| +4% | +$5.53K |
|
Similar funds
Legal & General Group's Q4 2019 Portfolio in Review
As of Q4 2019, Legal & General Group held 3,425 positions worth $210B, up 11% from $190B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Trading was light in Q4 2019: portfolio turnover was 3.9%. Legal & General Group opened 77 new positions and exited 57, leaving the 3,425-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.
- Legal & General Group's largest Q4 2019 buy was iShares MSCI Emerging Markets ETF: 425,000 shares worth $19.1M.
- Legal & General Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $261M increase.
- Legal & General Group's biggest Q4 2019 reduction was Oracle, cutting an estimated $25.8M.
- Legal & General Group fully exited Celgene Corp in Q4 2019, selling an estimated $415M.
- Legal & General Group's ten largest holdings make up 18% of its $210B portfolio in Q4 2019.
- Legal & General Group opened 77 new positions and closed 57 in Q4 2019.
- Legal & General Group's portfolio value rose 11% quarter-over-quarter to $210B.
Based on Legal & General Group's 13F filing for Q4 2019, filed 13 Feb 2020.